EpiTet is a novel immuno-epigenetic therapeutic platform. Designed to modulate disease-driving immune cells, it uses a small molecule-based approach to deplete epigenetically altered macrophages that perpetuate inflammation in chronic diseases. With applications in women’s health, metabolic diseases, and oncology, it is transforming the treatment paradigm for conditions where inflammation is both a driver and a barrier to recovery.

Impact Potential

EpiTet targets a pressing and underserved need in immunology by identifying and eliminating a subset of macrophages that are epigenetically programmed to drive chronic inflammation. These macrophages, or Toe-Macs (TET3 over-expressing macrophages), are induced in disease environments but are otherwise absent in healthy tissue. The lead compound, Epi-100, selectively depletes these cells, resulting in significant disease attenuation in animal models without side effects.

This approach is particularly promising in endometriosis, a condition affecting 10% of women and contributing to up to 50% of infertility cases. In MASH, where there is currently only one FDA-approved therapy, EpiTet’s solution offers a potential new line of treatment by targeting inflammation at its source. The same strategy is being extended into lung cancer and autoimmune diseases, where macrophage dysregulation plays a central role.

In the CEO's Words

“We’re not just suppressing inflammation; we’re teaching the immune system to forget its pathological patterns. Epi-100 represents a whole new modality to regulate disease from within. This progress has only been possible through a true team effort — from our scientific collaborators at Yale to the support of the Blavatnik Fund, Yale Ventures, and an extraordinary network of advisors and champions.” — Erika Smith, CEO, EpiTet